Immunogenic composition
US-9486515-B2 · Nov 8, 2016 · US
Immunogenic composition
US9931397B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9931397-B2 |
| Application number | US-91770906-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 23, 2006 |
| Priority date | Jun 27, 2005 |
| Publication date | Apr 3, 2018 |
| Grant date | Apr 3, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present application relates to an immunogenic composition comprising at least 2 conjugates of N. meningitidis capsular saccharide and protein carrier, wherein said conjugates comprise at least 2 different N. meningitidis capsular saccharides selected from the group consisting of MenA, MenC, MenY and MenW, wherein at least one capsular saccharide is conjugated to a protein carrier with a saccharide:protein ratio (w/w) between 1:2-1:5, and wherein at least one different capsular saccharide is conjugated to a protein carrier with a saccharide:protein ratio (w/w) between 5:1-1:1.99.
First claim
Opening claim text (preview).
The invention claimed is: 1. An immunogenic composition comprising conjugates of a plurality of N. meningitidis capsular saccharides and carrier protein, wherein said conjugates comprise a first N. meningitidis capsular saccharide which is N. meningitidis serogroup A capsular saccharide (MenA) or N. meningitidis serogroup C capsular saccharide (MenC), wherein the first N. meningitidis capsular saccharide is conjugated to a first carrier protein with a saccharide to carrie…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9931397B2 cover?
- The present application relates to an immunogenic composition comprising at least 2 conjugates of N. meningitidis capsular saccharide and protein carrier, wherein said conjugates comprise at least 2 different N. meningitidis capsular saccharides selected from the group consisting of MenA, MenC, MenY and MenW, wherein at least one capsular saccharide is conjugated to a protein carrier with a…
- Who is the assignee on this patent?
- Biemans Ralph Leon, Boutriau Dominique, Capiau Carine, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification A61K39/0017. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).